Fulgent Genetics, Inc.
For the period ended Dec 31, 2025. Filed Feb 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 27, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 3. Legal Proceedings
From time to time, we may be involved in legal proceedings arising in the ordinary course of our business. As disclosed in Note 8, Debt, Commitments and Contingencies, to our consolidated financial statements, we are engaged in certain legal investigations, and subject to audits. The disclosure set forth in Note 8, Debt, Commitments and Contingencies, to our consolidated financial statements included in this report relating to these certain legal matters is incorporated herein by reference.
The outcome of these matters are inherently uncertain, and there can be no assurances that a favorable outcome will be obtained.
Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity and reputational harm, among other factors.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.